A radioimmunoassay (RIA) is a laboratory technique that measures tiny quantities of substances in blood or other body fluids, most commonly hormones. It works by exploiting competition between a radioactively labeled version of the substance and the natural substance in a patient’s sample, both vying for a limited number of antibody binding sites. Developed in the late 1950s, RIA was the first method sensitive enough to detect hormones at concentrations as low as billionths of a gram per liter, and it earned Rosalyn Yalow the 1977 Nobel Prize in Physiology or Medicine.
How Competitive Binding Works
The core principle behind RIA is surprisingly simple. You start with three ingredients: an antibody that recognizes the substance you want to measure, a known amount of that substance tagged with a radioactive label (the “tracer”), and the patient’s sample containing an unknown amount of the same substance. When you mix them together, the labeled tracer and the unlabeled substance from the sample compete for the same antibody binding sites. The more of the substance present in the patient’s sample, the less tracer can attach to antibodies, because those binding sites are already occupied.
After an incubation period, you separate the antibody-bound molecules from the unbound ones and measure the radioactivity in each fraction. This gives you a ratio of bound to free tracer. By comparing that ratio against a standard curve, built by running the same process with known concentrations, you can calculate exactly how much of the substance was in the patient’s sample. A high radioactive signal in the bound fraction means the patient’s sample had very little of the target substance. A low signal means the sample was rich in it, since the patient’s own molecules displaced the tracer.
What It Measures
RIA was originally developed to measure insulin in the blood of diabetic patients. That breakthrough opened the door to measuring dozens of hormones and other biological molecules that exist in vanishingly small concentrations. If your blood has ever been tested for insulin, thyroid hormones, cortisol, testosterone, estradiol, or aldosterone, there’s a good chance the test used radioimmunoassay. Beyond hormones, RIA has been applied to detect drugs, vitamins (including B12), and immune markers. Its ability to pick up substances at concentrations in the picogram-per-milliliter range made it indispensable for endocrinology, oncology, and pharmacology research.
Step by Step in the Lab
A typical RIA follows a predictable sequence. First, a technician prepares a series of tubes containing known concentrations of the target substance (the standards) alongside tubes with the patient’s sample. A fixed amount of radioactively labeled tracer and a fixed amount of antibody are added to every tube. The tubes are then incubated, giving the labeled and unlabeled molecules time to compete for antibody binding sites. Incubation times vary by kit but can range from a few hours to overnight.
Once incubation is complete, the bound and free fractions need to be physically separated. A common approach uses a second antibody combined with a chemical called polyethylene glycol, which causes the antibody-bound complexes to clump together and settle out of solution as a precipitate. This technique works across different antibody types and takes only seconds for the reaction to occur. The liquid containing unbound tracer is then poured off, and the remaining precipitate is placed into a gamma counter, an instrument that detects the radiation emitted by the tracer. Iodine-125 is the most widely used radioactive label because its energy output and 60-day half-life are well suited to laboratory measurement.
Why It Was So Sensitive
Radioactive labels give RIA an edge in raw sensitivity that few techniques have matched. In one head-to-head comparison with ELISA (enzyme-linked immunosorbent assay), the most common non-radioactive alternative, RIA detected a test sample at a dilution of 1:102,400 while ELISA could only detect the same sample at 1:3,200. That roughly 32-fold difference in sensitivity comes from the extremely low background noise in radioactive counting. Gamma counters can distinguish genuine signal from background radiation with high precision, producing a clean signal-to-noise ratio that enzyme-based color or fluorescence readings struggle to match in certain applications.
This level of sensitivity matters most when the substance you’re measuring exists in extremely low concentrations, which is exactly the case for many hormones. Cortisol, insulin, and thyroid hormones circulate in the blood at levels where even small measurement errors can lead to misdiagnosis.
RIA vs. Modern Alternatives
Despite its sensitivity, RIA has been steadily replaced in most routine clinical laboratories. The main reason is practical: working with radioactive materials requires licensed facilities, strict waste disposal protocols, trained staff, and regulatory oversight from agencies like the U.S. Nuclear Regulatory Commission. These requirements add cost and complexity that many hospitals and commercial labs would rather avoid.
Chemiluminescent immunoassays and ELISA platforms have largely taken over routine hormone testing. Major diagnostic companies, including Siemens Healthineers, Abbott, and Roche Diagnostics, now build automated systems around these non-radioactive technologies. These platforms can process hundreds of samples per hour with minimal human handling, something RIA’s manual workflow can’t easily match.
That said, RIA hasn’t disappeared. Reference laboratories and research institutions still use it for specialized endocrine testing where its analytical sensitivity remains unmatched. In developing regions where automated chemiluminescent systems aren’t widely available, RIA remains a practical, cost-effective option. Its reagents are affordable, the equipment is relatively simple, and the results are reliable. Industry analysts expect this niche relevance to persist at least through the early 2030s.
Radioactive Tracers Used in RIA
The choice of radioactive label depends on the molecule being measured. Iodine-125 is the default for most protein and hormone assays because iodine atoms can be chemically attached to proteins without drastically changing their shape, which is critical since antibody recognition depends on three-dimensional molecular structure. Iodine-125 is preferred over iodine-131 because it emits lower-energy radiation (safer for lab workers) and has a longer half-life (giving kits a longer shelf life).
For smaller molecules that don’t contain convenient attachment points for iodine, other isotopes are used. Tritium (hydrogen-3), carbon-14, and phosphorus-32 can replace their stable counterparts within a molecule’s own structure. Vitamin B12, which contains a cobalt atom at its center, uses cobalt-57 or cobalt-58 as tracers. In rare cases, selenium-75 has been employed. Each isotope requires slightly different counting equipment, but the competitive binding principle stays the same.
Why RIA Won the Nobel Prize
Before Rosalyn Yalow and Solomon Berson developed RIA in the late 1950s, there was no reliable way to measure most hormones in human blood. Yalow, a physicist, had been using radioisotopes to study thyroid disease and iodine metabolism when she and Berson, an internist, noticed that diabetic patients treated with animal insulin developed antibodies against it. That observation led them to realize that the antibody-antigen reaction could be harnessed as a measurement tool if one version of the antigen carried a radioactive tag.
Their insulin assay was the proof of concept, but the method’s real impact was its universality. Any substance that triggers an immune response, or that an antibody can be raised against, can theoretically be measured by RIA. Within a decade, researchers had adapted the technique to measure dozens of hormones, drugs, and proteins. The Nobel committee recognized Yalow in 1977 specifically for “the development of radioimmunoassays of peptide hormones.” Berson had died in 1972 and was ineligible, as the prize is not awarded posthumously.